447 related articles for article (PubMed ID: 15056640)
1. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.
Wootton M; Bowker KE; Janowska A; Holt HA; MacGowan AP
J Antimicrob Chemother; 1999 Oct; 44(4):445-53. PubMed ID: 10588304
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
[TBL] [Abstract][Full Text] [Related]
4. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
Blondeau JM; Suter M; Borsos S
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Hoban DJ; Zhanel GG; Karlowsky JA
Diagn Microbiol Infect Dis; 1999 Sep; 35(1):37-44. PubMed ID: 10529880
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated in the UK from sputa.
Powell M; McVey D; Kassim MH; Chen HY; Williams JD
J Antimicrob Chemother; 1991 Aug; 28(2):249-59. PubMed ID: 1778856
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a prospective study in Murcia, Spain, 1983-1992.
Gómez J; Ruiz-Gómez J; Hernández-Cardona JL; Núñez ML; Canteras M; Valdés M
Chemotherapy; 1994; 40(5):299-303. PubMed ID: 7956452
[TBL] [Abstract][Full Text] [Related]
9. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.
Biedenbach DJ; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):349-53. PubMed ID: 9635909
[TBL] [Abstract][Full Text] [Related]
10. [Recent trends in incidence of respiratory tract pathogens and antimicrobial susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis isolated in 1994 and 1995].
Nishioka K; Ogihara H; Ohno I; Shirato K
Jpn J Antibiot; 1997 Sep; 50(9):768-75. PubMed ID: 9394237
[TBL] [Abstract][Full Text] [Related]
11. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998.
Sahm DF; Jones ME; Hickey ML; Diakun DR; Mani SV; Thornsberry C
J Antimicrob Chemother; 2000 Apr; 45(4):457-66. PubMed ID: 10747822
[TBL] [Abstract][Full Text] [Related]
12. Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. Alexander Project Group.
Schito GC; Mannelli S; Pesce A
J Chemother; 1997 May; 9 Suppl 3():18-28. PubMed ID: 9248977
[TBL] [Abstract][Full Text] [Related]
13. Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland.
Manninen R; Huovinen P; Nissinen A
J Antimicrob Chemother; 1997 Sep; 40(3):387-92. PubMed ID: 9338492
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Thornsberry C; Ogilvie P; Kahn J; Mauriz Y
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982
[TBL] [Abstract][Full Text] [Related]
15. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
Thornsberry C; Jones ME; Hickey ML; Mauriz Y; Kahn J; Sahm DF
J Antimicrob Chemother; 1999 Dec; 44(6):749-59. PubMed ID: 10590275
[TBL] [Abstract][Full Text] [Related]
16. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.
Davies TA; Kelly LM; Jacobs MR; Appelbaum PC
J Clin Microbiol; 2000 Apr; 38(4):1444-8. PubMed ID: 10747123
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Brueggemann AB; Doern GV; Huynh HK; Wingert EM; Rhomberg PR
Antimicrob Agents Chemother; 2000 Feb; 44(2):447-9. PubMed ID: 10639382
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
Doern GV; Vautour R
Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
[TBL] [Abstract][Full Text] [Related]
19. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.
Felmingham D; Grüneberg RN
J Antimicrob Chemother; 2000 Feb; 45(2):191-203. PubMed ID: 10660501
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.
Bryan JP; Waters C; Sheffield J; Wagner KF
Eur J Clin Microbiol Infect Dis; 1990 May; 9(5):361-5. PubMed ID: 2142647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
